Low LDL But Heart Attack Risk: Check AIP Now

Audio updated March 29, 2026, for Apple device compatibility.

Low LDL is important—but it’s not the whole story. In this episode, we’ll look at a study showing that even when LDL is below 70, your triglycerides, HDL, and AIP can still predict stents and heart attacks—and what you can do now to improve AIP.

🎧 ▶️ Press the play button below to listen in English.

🇨🇳 中文(简体)

🇪🇸 Spanish (Latinoamérica)

I. Introduction: Low LDL-C Isn’t the Finish Line

For years, LDL‑C (“bad cholesterol”) has been treated as the headline number for preventing heart attacks. Lowering LDL‑C reduces risk—but a dangerous conclusion has quietly taken hold: if my LDL‑C is perfect, I’m safe.

Real‑world cardiology tells a different story. Patients can hit their LDL‑C goal and still suffer a heart attack—and some still end up needing a stent.

A 2023 study by Wang et al. focused exclusively on people who already had optimal LDL‑C below 1.8 mmol/L (70 mg/dL) . Every single patient in the study presented with acute coronary syndrome (ACS) and underwent percutaneous coronary intervention (PCI)—a procedure where cardiologists open a narrowed artery and place a stent.

This paper matters because it doesn’t argue against lowering LDL. It argues against LDL‑only thinking.

Diagram showing that heart risk can persist even with low LDL, especially when triglycerides are high, HDL is low, and AIP is elevated. loading=
Even with “optimal” LDL, triglycerides, HDL, and AIP can reveal residual ASCVD risk.

II. The Key Finding: AIP Predicted Risk When LDL Didn’t

In this retrospective cohort of 1,133 ACS patients with LDL‑C < 1.8 mmol/L who underwent PCI, the researchers asked a practical question:

When LDL‑C is already at goal, what still predicts trouble ahead?

Their answer was the Atherogenic Index of Plasma (AIP) —a simple number calculated from a standard lipid panel:

AIP = log (Triglycerides / HDL‑C)

AIP matters because it reflects the metabolic side of lipid risk—especially higher triglycerides (TG) and lower HDL‑C, a pattern often linked to insulin resistance and smaller, denser, more atherogenic lipoproteins.

Over a median follow‑up of 26 months, people with higher AIP had more adverse outcomes:

  • MACCE (major adverse cardiovascular and cerebrovascular events) occurred more often in the high‑AIP group: 9.6% vs 6.0%.
  • The difference was driven mainly by unplanned repeat revascularization—meaning they needed another procedure to restore blood flow: 7.6% vs 4.6%.

Even after adjusting for multiple risk factors, higher AIP still predicted higher risk.

The message is clear: LDL‑C can be “great,” yet the patient can still be on a path toward more stents and greater danger—if the TG/HDL pattern remains unhealthy.


III. How Can LDL Be Low but Risk Still High?

Hitting an LDL‑C target below 1.8 mmol/L is often treated like the finish line. But LDL‑C is only one piece of lipid risk. Here’s how risk can persist:

A. Medication is doing its job

Nearly everyone in the study was on a statin. Yet outcomes still differed by AIP, not by LDL‑C. Lowering LDL is necessary but doesn’t erase risk from triglycerides, HDL, insulin resistance, or inflammation.

B. Atherogenic dyslipidemia

A common pattern in insulin resistance and metabolic syndrome includes:

  • Higher triglycerides
  • Lower HDL‑C
  • More small, dense LDL particles

This pattern can exist even when LDL‑C is low—and it’s exactly what AIP captures.

In the study, the high‑AIP group had:

  • Lower HDL‑C (0.9 vs 1.1 mmol/L)
  • Higher TG (1.8 vs 0.9 mmol/L)
  • LDL‑C was essentially the same in both groups (around 1.5 mmol/L)

LDL‑C didn’t separate risk. TG and HDL—and therefore AIP—did.

C. Insulin resistance

The high‑AIP group had more diabetes (46.7% vs 38.9%) and higher HbA1c. AIP is strongly associated with insulin resistance, which raises susceptibility to cardiovascular events.

D. Secondary prevention

This wasn’t a healthy population. These were people with active ACS undergoing PCI. Coronary disease isn’t just about today’s LDL level—it’s about plaque burden, instability, and residual risk even after LDL is controlled.

Four-step visual explaining PCI with balloon angioplasty and stent placement to open a narrowed coronary artery.
PCI restores blood flow quickly, but it doesn’t cure the underlying plaque process.

IV. What Are PCI and Stents—and What They Don’t Do

PCI (percutaneous coronary intervention) is a catheter‑based procedure to restore blood flow in a blocked coronary artery. A stent—usually a drug‑eluting stent (DES)—is placed to keep the artery open.

PCI treats a blockage. It does not cure coronary artery disease.

Think of it like rust in plumbing: PCI opens one narrowed segment, but the biological process that created the plaque—metabolic dysfunction, inflammation, insulin resistance—can continue.

This is called residual risk: even after LDL is controlled and the artery is opened, events can still occur.

How long do stents last?

A stent is not a lifetime guarantee. Patients can end up back in the cath lab for two main reasons:

  1. In‑stent restenosis – narrowing at the stent site.
  2. Progression of plaque elsewhere – new plaques in other arteries.

In this study, over a median of 26 months:

  • 69 unplanned repeat revascularizations occurred out of 88 total MACCE events.
  • Repeat procedures were the dominant “bad outcome.”
  • Higher AIP predicted who was more likely to need them.

V. Study at a Glance

ItemDetails
Population1,133 ACS patients who underwent PCI
LDL‑CAll below 1.8 mmol/L (70 mg/dL)
AIP cut pointMedian ~0.11 (low vs high)
Primary outcomeMACCE (death, MI, stroke, unplanned repeat revascularization)
Follow‑upMedian 26 months
Key findingHigher AIP → more MACCE and repeat revascularization, even with same LDL
Summary of the study showing higher AIP linked with higher MACCE and repeat revascularization despite LDL below 70 mg/dL.
In this cohort, LDL was already “optimal,” but AIP still separated higher vs lower risk outcomes.

VI. The AIP Calculator (Interactive Tool + Guidepost Values)

Visual explaining AIP inputs (triglycerides and HDL), formula, and unit conversions with an example calculation.
AIP is calculated from TG and HDL—two routine lipid numbers—then interpreted using guideposts.

AIP is calculated from a standard lipid panel—no advanced testing required.

AIP = log₁₀ (Triglycerides / HDL‑C)

Use the same units for TG and HDL (mmol/L is standard).

Guidepost values:

  • AIP < 0.11 → Lower risk
  • AIP 0.11 – 0.21 → Intermediate risk
  • AIP > 0.21 → Higher risk

In the Wang study, the median cut point was approximately 0.11. The group with AIP ≥ 0.11 had significantly worse outcomes.

If your AIP is drifting upward—especially above 0.11—don’t ignore it just because your LDL looks great.

Atherogenic Index (AIP) Calculator

Calculates AIP = log10(Triglycerides ÷ HDL) using mmol/L internally.


VII. How to Improve Your AIP (Before You Need a Stent)

If AIP is high, the goal isn’t to “treat a number.” It’s to change the metabolic environment that drives plaque growth, instability, and repeat procedures.

AIP improves when triglycerides go down and HDL rises—changes that usually happen when insulin resistance improves.

A. Lower triglycerides (fastest lever)

  1. Cut sugar and refined starch
    Sugary drinks, desserts, white bread, rice, pasta, and frequent carb snacking are major TG drivers.
  2. Reduce alcohol
    Alcohol raises TG in many people, especially when combined with carbs.
  3. Don’t be fooled by “low fat”
    A low‑fat diet can still produce high TG if it’s high in starch and sugar.
  4. Prioritize protein and fiber
    Build meals around protein, vegetables, and healthy fats.

B. Raise HDL

  1. Exercise consistently – brisk walking, cycling, swimming, resistance training 4–6 days/week.
  2. Stop smoking – smoking lowers HDL and damages arteries.
  3. Improve sleep and stress – chronic sleep deprivation and stress worsen insulin resistance and TG/HDL patterns.

C. Fix insulin resistance

AIP often reflects insulin resistance. Strategies that help:

  • Reduce central/visceral fat
  • Strength training (build muscle to improve glucose disposal)
  • Avoid frequent high‑carb snacking
  • Time carbs around activity, not late at night
  • Track fasting glucose, HbA1c, and fasting insulin if available
AIP risk gauge showing low, intermediate, and high zones with cut points at 0.11 and 0.21.
Use these AIP guideposts to interpret your TG/HDL pattern at a glance.

Side-by-side comparison showing two people with the same low LDL but different triglycerides, HDL, and AIP risk profiles.
LDL can look great in both cases—but TG/HDL and AIP can reveal residual risk.

VIII. A Simple AIP Improvement Checklist

If you want a short plan you can actually follow:

  1. Eliminate sugary drinks and desserts for 30 days
  2. Make every meal protein‑first
  3. Walk 10–20 minutes after your biggest meal
  4. Lift weights (or do resistance work) 2–4 times per week
  5. Limit alcohol (especially alcohol + carbs)
  6. Recheck TG, HDL, and AIP in 6–12 weeks
Checklist of lifestyle actions to lower triglycerides, support HDL, and improve AIP with a suggested recheck timeline.
Improving AIP is mostly about improving insulin sensitivity and the TG/HDL pattern—starting today.

IX. Bottom Line

LDL‑C matters—but it’s not the whole story. This study shows that even when LDL‑C is “optimized” below 1.8 mmol/L, the metabolic pattern captured by AIP still predicts who will have more heart attacks and who will need repeat stents.

Don’t wait until you hear:

  • “You need a cath.”
  • “You need a stent.”
  • “You need another procedure.”

Improve your AIP now—so you never need the PCI in the first place.


Timeline showing progression from high AIP and metabolic risk to ACS and PCI, emphasizing early prevention.
The best time to improve AIP is before symptoms—so you never need the stent.

Don’t Get Sick!

Medically Reviewed by Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on FacebookGabTwitter (formerly known as X), and Telegram.

Related:

References:

  • Wang Y, Wang S, Sun S, Li F, Zhao W, Yang H, Wu X. The predictive value of atherogenic index of plasma for cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention with LDL-C below 1.8mmol/L. Cardiovasc Diabetol. 2023 Jun 26;22(1):150. doi: 10.1186/s12933-023-01888-3. PMID: 37365588; PMCID: PMC10294439. https://pubmed.ncbi.nlm.nih.gov/37365588/

Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.

© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment


Discover more from Don't Get Sick!

Subscribe to get the latest posts sent to your email.